journal article·2025-12Open access

Tumor-homing exosomes enable targeted delivery of siRNA and isoimperatorin for overcoming BTK inhibitor resistance in DLBCL

Ruowen Sun, Yanchao Yang, Bin Zhang, Jiayuan Chen, Ye Wang, Zehui Jiang, Linlin Zhang, Milad Ashrafizadeh, Gautam Sethi, Jing Shen, Zuofei Chi

Abstract

Diffuse large B-cell lymphoma (DLBCL) is the most common type of lymphoma, but over one-third of patients relapse or develop refractory disease after first-line therapy. Novel therapeutic strategies are required to address persistent unmet clinical needs for DLBCL. This study aimed to develop an exosome-based drug delivery system for the targeted combination therapy of siRNA against Bruton's tyrosine kinase (BTK, an established therapeutic target in B cell lymphomas) and isoimperatorin (ISOIM, an active natural furanocoumarin showing anti-tumor effects) in DLBCL. Tumor exosomes were isolated as the delivery carrier. ISOIM/siBTK@Exosome was prepared by encapsulating ISOIM and si-BTK into exosome using electroporation. Cellular uptake, immune escape, targeted delivery efficiency, anti-lymphoma activity and biosafety of ISOIM/siBTK@Exosome were evaluated in two DLBCL cell lines and in tumor-bearing mice. ISOIM/siBTK@Exosome displayed significant anti-lymphoma activity compared to ISOIM@Exosome or siBTK@Exosome alone, demonstrating synergistic therapeutic role of ISOIM and si-BTK. Besides, ISOIM/siBTK@Exosome can accelerate T cells activation and prevent macrophage M2 polarization in vitro. Administration of ISOIM/siBTK@Exosome to tumor-bearing mice significantly inhibited tumor growth and prolonged survival. The ISOIM/siBTK@Exosome was biocompatible and biosafe in vivo without damage on the major organs in H&E staining. The prepared ISOIM/siBTK@Exosome may provide novel targeted therapeutic strategy to be applied in the clinical management of patients with DLBCL.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: RNA Interference and Gene Delivery · Extracellular vesicles in disease · Cell Adhesion Molecules Research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (65)

Show source-provided references
1. Non-Hodgkin lymphoma10.1016/S0140-6736(16)32407-2 ↗
2. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
3. Burden of lymphoma in China, 1990-2019: an analysis of the global burden of diseases, injuries, and risk factors study 201910.18632/aging.204006 ↗
4. Diffuse large B-cell lymphoma10.1002/hon.3202 ↗
5. How I treat older patients with relapsed/refractory diffuse large B-cell lymphoma10.1182/blood.2024024788 ↗
6. Genetic and transcriptomic analyses of diffuse large B-cell lymphoma patients with poor outcomes within two years of diagnosis10.1038/s41375-023-02120-7 ↗
7. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma10.1038/nm.3884 ↗
8. CD30 protects EBV-positive diffuse large B-cell lymphoma cells against mitochondrial dysfunction through BNIP3-mediated mitophagy10.1016/j.canlet.2024.216616 ↗
9. Targeting the B cell receptor pathway in non-Hodgkin lymphoma10.1080/13543784.2018.1482273 ↗
10. Targeting the B-cell receptor pathway in diffuse large B-cell lymphoma10.1016/j.ctrv.2018.01.002 ↗
11. Role of Bruton's tyrosine kinase in B cells and malignancies10.1186/s12943-018-0779-z ↗
12. Bruton tyrosine kinase inhibitors in B-cell malignancies: their use and differential features10.1007/s11523-021-00857-8 ↗
13. Bruton's tyrosine kinase inhibitors (BTKIs): review of preclinical studies and evaluation of clinical trials10.3390/molecules28052400 ↗
14. Abivertinib, a novel BTK inhibitor: anti-Leukemia effects and synergistic efficacy with homoharringtonine in acute myeloid leukemia10.1016/j.canlet.2019.07.008 ↗
15. Dermatological toxicities of Bruton's tyrosine kinase inhibitors10.1007/s40257-020-00535-x ↗
16. Mechanisms of resistance to noncovalent Bruton's tyrosine kinase inhibitors10.1056/NEJMoa2114110 ↗
17. Enhancing siRNA cancer therapy: multifaceted strategies with lipid and polymer-based carrier systems10.1016/j.ijpharm.2024.124545 ↗
18. Challenges and opportunities for siRNA-based cancer treatment10.1016/j.canlet.2016.03.045 ↗
19. The landscape of nanoparticle-based siRNA delivery and therapeutic development10.1016/j.ymthe.2024.01.005 ↗
20. Nanoparticles and siRNA: a new era in therapeutics?10.1016/j.phrs.2024.107102 ↗
21. Exosome-based nanoparticles and cancer immunotherapy10.1016/j.biopha.2024.117296 ↗
22. Engineering exosomes for targeted drug delivery10.7150/thno.52570 ↗
23. Exosomes: large-scale production, isolation, drug loading efficiency, and biodistribution and uptake10.1016/j.jconrel.2022.05.027 ↗
24. Exosome-like systems: nanotechnology to overcome challenges for targeted cancer therapies10.1016/j.canlet.2023.216151 ↗
25. Exosome-mediated delivery of transforming growth factor-β receptor 1 kinase inhibitors and toll-like receptor 7/8 agonists for combination therapy of tumors10.1016/j.actbio.2022.01.005 ↗
26. Natural products: promising resources for cancer drug discovery10.2174/187152012798764697 ↗
27. Antiviral activity of isoimperatorin against influenza A virus in vitro and its inhibition of neuraminidase10.3389/fphar.2021.657826 ↗
28. Isoimperatorin inhibits angiogenesis by suppressing VEGFR2 signaling pathway
29. Isoimperatorin alleviates lipopolysaccharide-induced periodontitis by downregulating ERK1/2 and NF-κB pathways
30. Isoimperatorin down-regulates epithelial mesenchymal transition through modulating NF-κB signaling and CXCR4 expression in colorectal and hepatocellular carcinoma cells10.1016/j.cellsig.2022.110433 ↗
31. Isoimperatorin induces apoptosis of the SGC-7901 human gastric cancer cell line via the mitochondria-mediated pathway10.3892/ol.2016.5387 ↗
32. Effects of isoimperatorin on proliferation and apoptosis of human gastric carcinoma cells
33. Apoptotic effect of isoimpertorin via inhibition of c-Myc and SIRT1 signaling Axis10.3390/ijms25084248 ↗
34. Construction of homologous cancer cell membrane camouflage in a nano-drug delivery system for the treatment of lymphoma10.1186/s12951-020-00738-8 ↗
35. Controlled drug delivery systems: past forward and future back10.1016/j.jconrel.2014.03.054 ↗
36. Liposomal drug delivery systems: from concept to clinical applications10.1016/j.addr.2012.09.037 ↗
37. Targeted drug delivery strategies for precision medicines10.1038/s41578-020-00269-6 ↗
38. Drug delivery to the central nervous system10.1038/s41578-021-00394-w ↗
39. The blood–brain barrier: structure, regulation and drug delivery10.1038/s41392-023-01481-w ↗
40. Safe nanoparticles: are we there yet?10.3390/ijms22010385 ↗
41. Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system10.1016/0169-409X(95)00039-A ↗
42. Zwitterionic‐coated “stealth” nanoparticles for biomedical applications: recent advances in countering biomolecular corona formation and uptake by the mononuclear phagocyte system10.1002/smll.201303540 ↗
43. Exosome engineering in cell therapy and drug delivery10.1007/s10787-022-01115-7 ↗
44. Extracellular vesicles as a next-generation drug delivery platform10.1038/s41565-021-00931-2 ↗
45. Functionalized exosome harboring bioactive molecules for cancer therapy10.1016/j.canlet.2020.05.036 ↗
46. Tumor cell-derived exosomes home to their cells of origin and can be used as Trojan horses to deliver cancer drugs10.7150/thno.39434 ↗
47. Advances in exosome-based drug delivery and tumor targeting: from tissue distribution to intracellular fate10.2147/IJN.S281890 ↗
48. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis10.1016/j.cell.2009.05.046 ↗
49. Exosome-SIRPα, a CD47 blockade increases cancer cell phagocytosis10.1016/j.biomaterials.2017.01.004 ↗
50. Exosomal CD47 plays an essential role in immune evasion in ovarian cancer10.1158/1541-7786.MCR-20-0956 ↗
51. Extracellular vesicles: a rising star for therapeutics and drug delivery10.1186/s12951-023-01973-5 ↗
52. Tumor cell-derived exosomes deliver TIE2 protein to macrophages to promote angiogenesis in cervical cancer10.1016/j.canlet.2022.01.005 ↗
53. Cancer cell-derived exosome based dual-targeted drug delivery system for non-small cell lung cancer therapy10.1016/j.colsurfb.2024.114141 ↗
54. Synergistic phototherapy-molecular targeted therapy combined with tumor exosome nanoparticles for oral squamous cell carcinoma treatment10.3390/pharmaceutics16010033 ↗
55. Tumor exosome-based nanoparticles are efficient drug carriers for chemotherapy10.1038/s41467-019-11718-4 ↗
56. Drug loading techniques for exosome-based drug delivery systems
57. Current strategies for exosome cargo loading and targeting delivery10.3390/cells12101416 ↗
58. Kumar · 2019
59. Unveiling the PDK4-centered rituximab-resistant mechanism in DLBCL: the potential of the "Smart" exosome nanoparticle therapy10.1186/s12943-024-02057-0 ↗
60. Safety and efficacy of pembrolizumab in combination with acalabrutinib in advanced head and neck squamous cell carcinoma: phase 2 proof-of-concept study10.1158/1078-0432.CCR-21-2547 ↗
61. A Tec kinase BTK inhibitor ibrutinib promotes maturation and activation of dendritic cells10.1080/2162402X.2016.1151592 ↗
62. Spatially-resolved transcriptomics reveal macrophage heterogeneity and prognostic significance in diffuse large B-cell lymphoma10.1038/s41467-024-46220-z ↗
63. Tumor-associated macrophages predict prognosis in diffuse large B-cell lymphoma and correlation with peripheral absolute monocyte count10.1186/s12885-019-6208-x ↗
64. Prognostic influence of macrophages in patients with diffuse large B-cell lymphoma: a correlative study from a Nordic phase II trial10.3324/haematol.2014.113472 ↗
65. Inflammatory cells in diffuse large B cell lymphoma10.3390/jcm9082418 ↗